Protein / target

Epidermal growth factor receptor

EGFRP00533Homo sapiensSwiss-Prot
UniProt: P00533Ensembl: ENSG00000146648HGNC: HGNC:3236NCBI Gene: 1956
Clinically validated
Therapeutic maturity
28
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Transmembrane receptor protein tyrosine kinase activity

Primary system

Nervous system

Strongest disease association

head and neck squamous cell carcinoma

Genetic evidence · score 0.82

Therapeutic maturity

Clinically validated target

28 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

28 approved · 53 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:10805725, PubMed:27153536, PubMed:2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity)

Subcellular location

Cell membraneEndoplasmic reticulum membraneGolgi apparatus membraneNucleus membraneEndosomeEndosome membraneNucleusSecreted
Domains and Gene Ontology detail (84)

Domains & features

Protein kinase

Gene Ontology

  • Cbasal plasma membrane
  • Cbasolateral plasma membrane
  • Ccell junction
  • Ccell surface
  • Cclathrin-coated endocytic vesicle membrane
  • Ccytoplasm
  • Cearly endosome membrane
  • Cendoplasmic reticulum membrane
  • Cendosome
  • Cendosome membrane
  • Cextracellular space
  • Cfocal adhesion

1210 aa · 134 kDa · 4 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Kinase signallingUniProt · GOCell adhesionGOTranscriptional regulationGOG protein-coupled signallingUniProtApoptosis & cell deathGOMuscle contractionGO
View supporting evidence

Kinase signalling

  • ·Receptor tyrosine kinase binding ligands of the EGF family and activating several signal…
  • ·MAP kinase kinase kinase activity
  • ·protein tyrosine kinase activity
  • ·transmembrane receptor protein tyrosine kinase activity

Cell adhesion

  • ·cell junction
  • ·cell-cell adhesion

Transcriptional regulation

  • ·positive regulation of miRNA transcription
  • ·positive regulation of transcription by RNA polymerase II

G protein-coupled signalling

  • ·Receptor tyrosine kinase binding ligands of the EGF family and activating several signal…

Apoptosis & cell death

  • ·negative regulation of apoptotic process

Muscle contraction

  • ·actin filament binding
View underlying pathways (25)
Signaling by ERBB2
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
Signaling by ERBB4
SHC1 events in ERBB2 signaling
PLCG1 events in ERBB2 signaling
PIP3 activates AKT signaling
Signaling by EGFR
GRB2 events in EGFR signaling
GAB1 signalosome
SHC1 events in EGFR signaling
EGFR downregulation
GRB2 events in ERBB2 signaling
PI3K events in ERBB2 signaling
EGFR interacts with phospholipase C-gamma
EGFR Transactivation by Gastrin

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

PTPN11HBEGFNRG1TGFAERBB2DCNSHC1SOS1PIK3CAERBB3EGFR

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

10

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

gefitinib
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving non-small cell lung carcinoma, non-small cell lung carcinoma, neoplasm, head and neck squamous cell carcinoma

Direct interaction with this protein · Only this protein recorded as a target

osimertinib
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving non-small cell lung carcinoma, non-small cell lung carcinoma, neoplasm, melanoma

Direct interaction with this protein · Only this protein recorded as a target

amivantamab
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving non-small cell lung carcinoma, non-small cell lung carcinoma, non-small cell lung carcinoma, neoplasm

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

nimotuzumab
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving head and neck cancer, glioblastoma, head and neck squamous cell carcinoma, nasopharyngeal neoplasm

Direct interaction with this protein · Only this protein recorded as a target

Erlotinib Hydrochloride
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving non-small cell lung carcinoma, pancreatic neoplasm, non-small cell lung carcinoma, exocrine pancreatic carcinoma

Direct interaction with this protein · Only this protein recorded as a target

pyrotinib
Narrow target profilePhase 3Inhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving breast cancer, non-small cell lung carcinoma, lung adenocarcinoma, non-small cell lung carcinoma

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

mobocertinib
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving non-small cell lung carcinoma, neoplasm, non-small cell lung carcinoma, lung adenocarcinoma

Direct interaction with this protein · Only this protein recorded as a target

neratinib
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving neoplasm, breast cancer, non-small cell lung carcinoma, glioblastoma

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

brigatinib
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving non-small cell lung carcinoma, anaplastic large cell lymphoma, non-small cell lung carcinoma, non-small cell lung carcinoma

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

lazertinib
Narrow target profileApprovedInhibitor

Epidermal growth factor receptor erbB1 inhibitor

Appears in clinical studies involving non-small cell lung carcinoma, neoplasm, non-small cell lung carcinoma, lung adenocarcinoma

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

head and neck squamous cell carcinoma0.82

Genetic · overall 0.73

lung cancer0.79

Genetic · overall 0.72

inflammatory skin and bowel disease, neonatal, 20.79

Genetic · overall 0.64

non-small cell lung carcinoma0.75

Genetic · overall 0.85

lung adenocarcinoma0.72

Genetic · overall 0.77

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

neoplasm0.97

Clinical · overall 0.65

breast cancer0.96

Clinical · overall 0.68

colorectal adenocarcinoma0.86

Clinical · overall 0.68

cancer0.79

Clinical · overall 0.74

glioblastoma0.63

Clinical · overall 0.65

Show all associations
non-small cell lung carcinoma0.85
lung adenocarcinoma0.77
cancer0.74
head and neck squamous cell carcinoma0.73
lung cancer0.72
breast cancer0.68
colorectal adenocarcinoma0.68
glioblastoma0.65
neoplasm0.65
inflammatory skin and bowel disease, neonatal, 20.64

Open Targets ranks 6,459 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 82 total

RUSERONTINIBPhase 3

acute myeloid leukemia · neoplasm

TESEVATINIBPhase 3

non-small cell lung carcinoma · non-small cell lung carcinoma · polycystic kidney disease

AFATINIBApproval

non-small cell lung carcinoma · neoplasm · non-small cell lung carcinoma

CETUXIMAB SAROTALOCANApproval

head and neck cancer · head and neck squamous cell carcinoma · head and neck squamous cell carcinoma

MDX-447Phase 1

glioblastoma

ALLITINIBPhase 1
BRIGATINIBApproval

non-small cell lung carcinoma · anaplastic large cell lymphoma · non-small cell lung carcinoma

LAZERTINIBApproval

non-small cell lung carcinoma · neoplasm · non-small cell lung carcinoma

IMGATUZUMABPhase 2

metastatic colorectal cancer · non-small cell lung carcinoma · colorectal cancer

AFATINIB DIMALEATEApproval

non-small cell lung carcinoma · non-small cell lung carcinoma · breast cancer

Tractability

SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · Approved DrugAB · UniProt loc high confAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · Literature

Safety liabilities

alopeciaocular keratitisHepatotoxicitySkin rashdiarrhoeaDiarrheaAST increaseregulation of catalytic activityepithelial inflammationdrug toxicitydecreased appetiterash

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.PHASE2

RECRUITING · via osimertinib · NCT04322890

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)PHASE2

RECRUITING · via osimertinib · NCT05642572

A Randomized Open-Label Phase II Trial of Pemetrexed and a Platinum (Carboplatin or Cisplatin) With or Without Erlotinib in Patients With Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations and Acquired Resistance to First-Line EGFR TKIs, Erlotinib or GefitinibPHASE2

WITHDRAWN · via Erlotinib Hydrochloride · NCT01928160

A Phase I Dose-Escalation Study of Erlotinib in Combination With Dasatinib in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.PHASE1

COMPLETED · via Erlotinib Hydrochloride · NCT00895128

LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the LungPHASE2

COMPLETED · via gefitinib · NCT01466660

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)PHASE2

RECRUITING · via osimertinib · NCT05281406

Show remaining trials (24)
A Randomized, Multicenter, Open-label Clinical Study Using Peripheral Blood Circulating Tumor DNA to Evaluate the Efficacy of Preoperative Treatment With Pyrotinib + Trastuzumab + Docetaxel Versus Pertuzumab + Trastuzumab + Docetaxel in Early or Locally Advanced HER2-positive Breast CancerPHASE2

RECRUITING · via pyrotinib · NCT07335081

A Clinical Trial of Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung CancerNA

RECRUITING · via osimertinib · NCT06304441

Adjuvant Dual Anti-HER2 Therapy in Patients With Tumors < 8mm, Node-negative, HER2-positive Breast Cancer :a Single-group Arm, Open-label, Prospective, Phase 2 StudyPHASE2

NOT_YET_RECRUITING · via pyrotinib · NCT04158856

Efficacy and Safety of Radiotherapy Concurrently Combined With Cisplatin and Nimotuzumab for Patients With Locally Advanced Cervical CancerPHASE2

UNKNOWN · via nimotuzumab · NCT02705612

An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell CarcinomasPHASE3

UNKNOWN · via nimotuzumab · NCT02611700

Randomized Phase II Study of First-Line Treatment With Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients With Stage IIIB/IV Non-Small Cell Lung CancerPHASE2

COMPLETED · via Erlotinib Hydrochloride · NCT00283244

A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase InhibitorsPHASE1/PHASE2

COMPLETED · via Erlotinib Hydrochloride · NCT01259089

Prospective, Multi-cohort, Exploratory Clinical Study of Pyrrotinib Maleate in HER2-positive Early Breast CancerNA

NOT_YET_RECRUITING · via pyrotinib · NCT06718335

Neoadjuvant Therapy With Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab or Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab Sequenced With Paclitaxel-based Regimens + Trastuzumab + Pyrotinib in HER2+ Breast CancerPHASE2

RECRUITING · via pyrotinib · NCT07393425

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamidePHASE2

COMPLETED · via neratinib · NCT02400476

A Randomized, Muticenter Double-blind Phase III Study of Neoadjuvant Pyrotinib Plus Trastuzumab and Docetaxel Compared With Placebo Plus Trastuzumab and Docetaxel in Women With HER2 Positive Early Stage or Locally Advanced Breast CancerPHASE3

COMPLETED · via pyrotinib · NCT03588091

An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With Advanced Breast CancerPHASE2

COMPLETED · via gefitinib · NCT00066378

Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old AgePHASE2

COMPLETED · via nimotuzumab · NCT06048913

A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And NeckPHASE1/PHASE2

COMPLETED · via Erlotinib Hydrochloride · NCT00055913

Phase I/II Clinical Trial of Combined Pre-Irradiation With Pemetrexed and Erlotinib Followed by Maintenance Erlotinib for Recurrent and Second Primary Squamous Cell Carcinoma of the Head and NeckPHASE1/PHASE2

TERMINATED · via Erlotinib Hydrochloride · NCT00573989

A Clinical Study of Nimotuzumab in Combination With Concurrent Chemotherapy and Radiation for Patients With Local Advanced Esophageal Squamous Cell CarcinomaPHASE2

UNKNOWN · via nimotuzumab · NCT01232374

Intercalated Combination of Erlotinib and Radiotherapy for Patients With EGFR-mutant, Unresectable, Locally Advanced Non-small-cell Lung CancerPHASE2/PHASE3

UNKNOWN · via Erlotinib Hydrochloride · NCT03074864

Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)PHASE1

COMPLETED · via osimertinib · NCT03535363

A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerPHASE2

ACTIVE_NOT_RECRUITING · via osimertinib · NCT03586453

A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI TherapyPHASE1/PHASE2

RECRUITING · via osimertinib · NCT07535437

A Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Metastatic Gemcitabine-Refractory Pancreatic CancerPHASE2

COMPLETED · via Erlotinib Hydrochloride · NCT00365144

A Phase III, Randomised, Double-blind, Multi-center Study to Assess the Efficacy and Safety of TY-9591 Tablets Versus Osimertinib as First Line Treatment in Patients With EGFR-sensitive Mutation, Locally Advanced or Metastatic Non Small Cell Lung Cancer.PHASE3

RECRUITING · via osimertinib · NCT05382728

Phase II Study to Evaluate the Tumor Biochemical Effects of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Erlotinib) Administered Prior to Surgical Resection in Patients With Early Stage Non-Small Cell Lung CancerPHASE2

TERMINATED · via Erlotinib Hydrochloride · NCT00087269

A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based ChemotherapyPHASE3

COMPLETED · via gefitinib · NCT00076388

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

non-small cell lung carcinomaWell supported
0.98
agreement 0.90–1.00
Clinical30%Genetic30%Somatic mutation22%Pathway13%Literature6%Genetic literaturedup

Open Targets aggregate 0.85 · 5 independent evidence families · 1 not counted as duplicate

head and neck squamous cell carcinomaWell supported
0.97
agreement 0.88–1.00
Genetic38%Clinical30%Somatic mutation14%Pathway11%Literature7%

Open Targets aggregate 0.73 · 5 independent evidence families

lung adenocarcinomaWell supported
0.96
agreement 0.88–1.00
Genetic32%Somatic mutation25%Clinical22%Pathway15%Literature7%

Open Targets aggregate 0.77 · 5 independent evidence families

lung cancerWell supported
0.96
agreement 0.87–1.00
Genetic39%Clinical31%Somatic mutation22%Literature7%Genetic literaturedup

Open Targets aggregate 0.72 · 4 independent evidence families · 1 not counted as duplicate

breast cancerWell supported
0.89
agreement 0.78–1.00
Clinical51%Genetic38%Literature11%

Open Targets aggregate 0.68 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

37

Recent activity around this target, drawn from one canonical event stream. Every item is reached through 10 drugs that target this protein, so each event is news about that drug rather than about the protein directly.

  1. Trial status changed2026-07-22

    Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

    Status changed to Terminated · ClinicalTrials.gov · via neratinib

  2. Regulatory approval2025-01-20

    Approval: Lazcluze (EMA)

    ema · regulatory · ema · via lazertinib

  3. Withdrawn from market2024-09-27

    Market withdrawal: Gefitinib Mylan (EMA)

    ema · market · ema · via gefitinib

  4. New publication2024-06-26
    Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC.

    The New England journal of medicine · 2024 · 303 citations · Europe PMC · via amivantamab

  5. New publication2023-10-31
    Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.

    BMJ (Clinical research ed.) · 2023 · 79 citations · Europe PMC · via pyrotinib

  6. New publication2023-08-30
    Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 37 citations · Europe PMC · via nimotuzumab

  7. New publication2023-06-01
    Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.

    Japanese journal of clinical oncology · 2023 · 59 citations · Europe PMC · via osimertinib

  8. New publication2023-01-31
    Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 308 citations · Europe PMC · via osimertinib

  9. New publication2022-12-08
    Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.

    Journal of hematology & oncology · 2022 · 271 citations · Europe PMC · via osimertinib

  10. New publication2021-12-16
    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

    JAMA oncology · 2021 · 233 citations · Europe PMC · via mobocertinib

  11. Regulatory approval2021-12-09

    Approval: Rybrevant (EMA)

    ema · regulatory · ema · via amivantamab

  12. New publication2021-09-16
    Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021 · 300 citations · Europe PMC · via brigatinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.